Literature DB >> 23690183

Comparing effects of citalopram with fluoxetine on sleep quality in patients with major depressive disorder.

E Shahsavand-Ananloo1, F Berenji, K Sadeghniiat, A Alimadadi, A R Zahiroddin, M Tabatabaee, M Abbasi-Asl, P Ghaeli.   

Abstract

BACKGROUND: Sleep disturbance is a common complaint in major depressive disorder (MDD) including impairment of both subjective and objective parameters. All antidepressants affect sleep architecture and quality. AIM: This trial was designed to compare the effects of short-term use of citalopram with fluoxetine on sleep quality (SQ) of patients with MDD based on Diagnostic and Statistical Manual for Mental Disorders - Text Revision 4th edition (DSM-IV-TR) criteria. PATIENTS AND METHODS: Patients who met the study criteria entered this open-label study. Sleep quality and depression severity were evaluated by using Pittsburgh Sleep Quality Index (PSQI) and Beck Depression Inventory-II (BDI-II), respectively. Patients could not have received any antidepressant for at least one month prior entering the study. Subjects were assigned to receive either fluoxetine or citalopram for 8 weeks. The relationships between SQ and severity of depression were also studied at weeks 4 and 8. Data was analyzed by using SPSS 11.5 version.
RESULTS: Nineteen patients received fluoxetine 20-40 mg/day and 21 received citalopram 20-40 mg/day. After 4 and 8 weeks treatment with both fluoxetine and citalopram, significant improvements in SQ were noted in both groups. However, no significant difference between the two groups was observed. Additionally, a significant and positive correlation between improvements in SQ and depression was noted after 8 weeks treatment with citalopram but not with fluoxetine.
CONCLUSIONS: This study noted that both citalopram and fluoxetine improved SQ in outpatients with MDD after 8 weeks without any significant difference between the 2 groups.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23690183

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  2 in total

1.  Efficacy and safety evaluation of citalopram and doxepin on sleep quality in comorbid insomnia and anxiety disorders.

Authors:  Junfeng Wu; Fei Chang; Hengbing Zu
Journal:  Exp Ther Med       Date:  2015-08-17       Impact factor: 2.447

Review 2.  Sleep loss as a factor to induce cellular and molecular inflammatory variations.

Authors:  Gabriela Hurtado-Alvarado; Lenin Pavón; Stephanie Ariadne Castillo-García; María Eugenia Hernández; Emilio Domínguez-Salazar; Javier Velázquez-Moctezuma; Beatriz Gómez-González
Journal:  Clin Dev Immunol       Date:  2013-12-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.